View ValuationDr. Martens 将来の成長Future 基準チェック /36Dr. Martens利益と収益がそれぞれ年間32.3%と4.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16% 33.5%なると予測されています。主要情報32.3%収益成長率33.55%EPS成長率Luxury 収益成長18.1%収益成長率4.6%将来の株主資本利益率16.00%アナリストカバレッジLow最終更新日20 May 2026今後の成長に関する最新情報お知らせ • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).すべての更新を表示Recent updatesお知らせ • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026お知らせ • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.お知らせ • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.お知らせ • Jun 18Dr. Martens plc to Report First Half, 2026 Results on Nov 20, 2025Dr. Martens plc announced that they will report first half, 2026 results on Nov 20, 2025お知らせ • Jun 17Dr. Martens plc, Annual General Meeting, Jul 10, 2025Dr. Martens plc, Annual General Meeting, Jul 10, 2025. Location: 1 11 hawley crescent, camden, nw1 8np, london United Kingdomお知らせ • Jun 05Dr. Martens plc Proposes Final Dividend for Fiscal Year 2025, Payable on 8 October 2025The Board of Dr. Martens plc proposed a final dividend of 1.70 pence, taking the total dividend for fiscal year 2025, including the interim dividend of 0.85 pence, to 2.55 pence (fiscal year 2024: 2.55 pence). This will be paid to shareholders on the register as at 29 August 2025 with payment on 8 October 2025. The proposed dividend is subject to shareholder approval.お知らせ • Feb 12Dr. Martens plc Announces the Appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors with Effect from 26 March 2025Dr. Martens plc announced the appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors of the Company with effect from 26 March 2025. Robert is an experienced executive with a strong track record of delivering growth at consumer brands. He was CEO of John Hardy and American Eagle Outfitters and also served as EVP Wines and Spirits for Constellation Brands. Prior to this he served for over a decade in senior roles at Levi Strauss & Co, including as President of the Americas division and, latterly, as Global Brand President, Americas. Robert brings a broad, multidisciplinary skillset and significant experience of the North American market combined with global expertise. His prior non-executive experience includes positions on the boards of Canopy Growth, Urban Outfitters and Constellation Brands. He was recently appointed as CEO of US wine company The Duckhorn Portfolio. Benoit is a Partner at the Company's largest investor, global investment firm Permira, where he is a member of the Investment and Executive Committees. He has served on the board of Spanish online travel company eDreams ODIGEO as a Non-Executive Director for a decade, during which time the business has undergone a significant period of transformation. Benoit also serves on the board of Permira Holdings Limited and has previously served on the boards of Universidad Europea, VacanceSelect and Exclusive Networks. He has worked at Permira since 2006, and previously spent six years at JPMorgan in London and Frankfurt.お知らせ • Dec 03Dr. Martens plc to Report Fiscal Year 2025 Results on Jun 05, 2025Dr. Martens plc announced that they will report fiscal year 2025 results on Jun 05, 2025お知らせ • Nov 28+ 1 more updateDr. Martens plc Announces Chief Executive Officer ChangesDr. Martens plc announced further to the company's previous announcement on 16 April 2024 that Ije Nwokorie would succeed Kenny Wilson as its new Chief Executive Officer before the end of the fiscal year 2025, Dr. Martens announced that Ije's appointment will take effect from 6 January 2025. The Company also confirms that Kenny Wilson will step down from the Board on 6 January 2025. Kenny will remain available to Ije and the wider Global Leadership Team until 31 March 2025 to ensure a smooth handover.お知らせ • Oct 08Dr. Martens plc to Report First Half, 2025 Results on Nov 28, 2024Dr. Martens plc announced that they will report first half, 2025 results on Nov 28, 2024お知らせ • Jun 14Dr. Martens plc, Annual General Meeting, Jul 11, 2024Dr. Martens plc, Annual General Meeting, Jul 11, 2024. Location: holiday inn london camden lock, 30 jamestown road, camden, nw1 7by, london United Kingdomお知らせ • Jun 05Dr. Martens plc Announces Executive ChangesDr. Martens plc announced that Katherine Bellau has been appointed as Company Secretary with effect from 3 June 2024. Katherine succeeds Emily Reichwald, who will be taking up a different role within the business.お知らせ • Jun 02Dr. Martens plc Proposes Final Dividend for Fiscal Year Ended 31 March 2024, Payable on 1 October 2024The board of Dr. Martens plc has proposed, subject to shareholder approval, a final dividend of 0.99 pence (fiscal year 2023: 4.28 pence), taking the total dividend for fiscal year ended 31 March 2024, including the interim dividend of 1.56 pence, to 2.55 pence, a 35% payout ratio. Whilst this is a year-on-year reduction given the higher payout in fiscal year 2023 and lower earnings achieved 2024, the 35% payout for fiscal year 2024 is at the top of the policy range. The board's intention is to hold the fiscal year 2025 dividend flat in absolute terms, before returning to an earnings payout in line with its dividend policy (of 25% to 35% payout) in fiscal year 2026 onwards. The final dividend for fiscal year 2024 will be paid to shareholders on the register as at 30 August 2024 with payment on 1 October 2024.お知らせ • May 21Marathon Partners Urges Dr. Martens to Buy Back StockOn May 20, 2024, Marathon Partners Equity Management announced that it is turning up the heat on Dr. Martens plc by urging the Company to detail planned expense cuts and to buy back stock.お知らせ • Apr 17Dr. Martens plc Announces CEO ChangesDr. Martens plc announced that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board announced that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season. Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of water UK.お知らせ • Apr 03Marathon Partners Calls for Strategic Review Process for Dr. MartensOn April 2, 2024, Marathon Partners Equity Management, LLC and its affiliated investment funds announced that they recently delivered a letter to Chairman Paul Mason and the Board of Directors, urging the Board to commence a process of evaluating alternatives to maximize shareholder value, including a potential sale of Dr. Martens plc. In the letter to the Board, Marathon Partners recommended that the Company’s Board hire an advisor and commence a strategic review process, including a potential sale or merger of the Company to interested parties, with the express goal of maximizing shareholder value. Marathon Partners stated that prior to the release of its letter, it held discussions with multiple Directors of the Company to privately resolve these matters. Marathon Partners also stated that while these conversations were friendly and productive, they did not lead to a satisfactory resolution of important shareholder issues.お知らせ • Feb 27Giles Wilson to Join Dr. Martens plc as CFO on May 27, 2024Dr. Martens plc announced that Giles Wilson, who has been appointed to the role of Chief Financial Officer (CFO), will join the business and Board on 27th May 2024 and will present the fiscal year 2024 results on 30th May 2024.お知らせ • Nov 30Dr. Martens plc Approves Interim Dividend, Payable on 2 February 2024Dr. Martens plc has approved and the Company has declared an interim dividend of 1.56p per share (2023: 1.56 pence). The interim dividend will be paid to shareholders on the register as at 5 January 2024 with payment on 2 February 2024.お知らせ • Nov 17+ 1 more updateDr. Martens plc Announces Management ChangesDr. Martens plc announced that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees. The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth. Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.お知らせ • Nov 14Dr. Martens plc to Report Fiscal Year 2024 Results on May 30, 2024Dr. Martens plc announced that they will report fiscal year 2024 results on May 30, 2024お知らせ • Jun 01+ 2 more updatesDr. Martens plc to Report First Half, 2024 Results on Nov 30, 2023Dr. Martens plc announced that they will report first half, 2024 results on Nov 30, 2023お知らせ • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).お知らせ • Jul 14Dr. Martens plc to Report Fiscal Year 2023 Results on Jun 01, 2023Dr. Martens plc announced that they will report fiscal year 2023 results on Jun 01, 2023業績と収益の成長予測OTCPK:DRMT.Y - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202987074617743/31/2028831616012153/31/202779049469843/29/202676524131143N/A12/29/202577520135148N/A9/28/202578515140154N/A6/28/202578610159175N/A3/30/20257885178196N/A12/30/202479717191212N/A9/29/202480629204227N/A6/29/202484249172197N/A3/31/202487769140168N/A12/31/20239278682120N/A9/30/20239781032472N/A6/30/20239891162272N/A3/31/20231,0001292173N/A12/31/202297915362105N/A9/30/2022957177104138N/A6/30/2022933179132161N/A3/31/2022908181159184N/A12/31/2021867118129151N/A9/30/20218255498117N/A6/30/202179944120138N/A3/31/202177335142159N/A12/31/202074761156175N/A9/30/202072287169190N/A6/30/202069781134156N/A3/31/202067275100121N/A3/31/201945417N/A56N/A3/31/2018349-6N/A46N/A3/31/2017291-11N/A34N/A3/31/2016232-12N/A26N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DRMT.Yの予測収益成長率 (年間32.3% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: DRMT.Yの収益 ( 32.3% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: DRMT.Yの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: DRMT.Yの収益 ( 4.6% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: DRMT.Yの収益 ( 4.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DRMT.Yの 自己資本利益率 は、3年後には低くなると予測されています ( 16 %)。成長企業の発掘7D1Y7D1Y7D1YConsumer-durables 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 03:13終値2026/05/13 00:00収益2026/03/29年間収益2026/03/29データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dr. Martens plc 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Richard TaylorBarclaysAnne CritchlowBerenbergDavid RouxBofA Global Research10 その他のアナリストを表示
お知らせ • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).
お知らせ • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026
お知らせ • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.
お知らせ • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.
お知らせ • Jun 18Dr. Martens plc to Report First Half, 2026 Results on Nov 20, 2025Dr. Martens plc announced that they will report first half, 2026 results on Nov 20, 2025
お知らせ • Jun 17Dr. Martens plc, Annual General Meeting, Jul 10, 2025Dr. Martens plc, Annual General Meeting, Jul 10, 2025. Location: 1 11 hawley crescent, camden, nw1 8np, london United Kingdom
お知らせ • Jun 05Dr. Martens plc Proposes Final Dividend for Fiscal Year 2025, Payable on 8 October 2025The Board of Dr. Martens plc proposed a final dividend of 1.70 pence, taking the total dividend for fiscal year 2025, including the interim dividend of 0.85 pence, to 2.55 pence (fiscal year 2024: 2.55 pence). This will be paid to shareholders on the register as at 29 August 2025 with payment on 8 October 2025. The proposed dividend is subject to shareholder approval.
お知らせ • Feb 12Dr. Martens plc Announces the Appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors with Effect from 26 March 2025Dr. Martens plc announced the appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors of the Company with effect from 26 March 2025. Robert is an experienced executive with a strong track record of delivering growth at consumer brands. He was CEO of John Hardy and American Eagle Outfitters and also served as EVP Wines and Spirits for Constellation Brands. Prior to this he served for over a decade in senior roles at Levi Strauss & Co, including as President of the Americas division and, latterly, as Global Brand President, Americas. Robert brings a broad, multidisciplinary skillset and significant experience of the North American market combined with global expertise. His prior non-executive experience includes positions on the boards of Canopy Growth, Urban Outfitters and Constellation Brands. He was recently appointed as CEO of US wine company The Duckhorn Portfolio. Benoit is a Partner at the Company's largest investor, global investment firm Permira, where he is a member of the Investment and Executive Committees. He has served on the board of Spanish online travel company eDreams ODIGEO as a Non-Executive Director for a decade, during which time the business has undergone a significant period of transformation. Benoit also serves on the board of Permira Holdings Limited and has previously served on the boards of Universidad Europea, VacanceSelect and Exclusive Networks. He has worked at Permira since 2006, and previously spent six years at JPMorgan in London and Frankfurt.
お知らせ • Dec 03Dr. Martens plc to Report Fiscal Year 2025 Results on Jun 05, 2025Dr. Martens plc announced that they will report fiscal year 2025 results on Jun 05, 2025
お知らせ • Nov 28+ 1 more updateDr. Martens plc Announces Chief Executive Officer ChangesDr. Martens plc announced further to the company's previous announcement on 16 April 2024 that Ije Nwokorie would succeed Kenny Wilson as its new Chief Executive Officer before the end of the fiscal year 2025, Dr. Martens announced that Ije's appointment will take effect from 6 January 2025. The Company also confirms that Kenny Wilson will step down from the Board on 6 January 2025. Kenny will remain available to Ije and the wider Global Leadership Team until 31 March 2025 to ensure a smooth handover.
お知らせ • Oct 08Dr. Martens plc to Report First Half, 2025 Results on Nov 28, 2024Dr. Martens plc announced that they will report first half, 2025 results on Nov 28, 2024
お知らせ • Jun 14Dr. Martens plc, Annual General Meeting, Jul 11, 2024Dr. Martens plc, Annual General Meeting, Jul 11, 2024. Location: holiday inn london camden lock, 30 jamestown road, camden, nw1 7by, london United Kingdom
お知らせ • Jun 05Dr. Martens plc Announces Executive ChangesDr. Martens plc announced that Katherine Bellau has been appointed as Company Secretary with effect from 3 June 2024. Katherine succeeds Emily Reichwald, who will be taking up a different role within the business.
お知らせ • Jun 02Dr. Martens plc Proposes Final Dividend for Fiscal Year Ended 31 March 2024, Payable on 1 October 2024The board of Dr. Martens plc has proposed, subject to shareholder approval, a final dividend of 0.99 pence (fiscal year 2023: 4.28 pence), taking the total dividend for fiscal year ended 31 March 2024, including the interim dividend of 1.56 pence, to 2.55 pence, a 35% payout ratio. Whilst this is a year-on-year reduction given the higher payout in fiscal year 2023 and lower earnings achieved 2024, the 35% payout for fiscal year 2024 is at the top of the policy range. The board's intention is to hold the fiscal year 2025 dividend flat in absolute terms, before returning to an earnings payout in line with its dividend policy (of 25% to 35% payout) in fiscal year 2026 onwards. The final dividend for fiscal year 2024 will be paid to shareholders on the register as at 30 August 2024 with payment on 1 October 2024.
お知らせ • May 21Marathon Partners Urges Dr. Martens to Buy Back StockOn May 20, 2024, Marathon Partners Equity Management announced that it is turning up the heat on Dr. Martens plc by urging the Company to detail planned expense cuts and to buy back stock.
お知らせ • Apr 17Dr. Martens plc Announces CEO ChangesDr. Martens plc announced that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board announced that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season. Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of water UK.
お知らせ • Apr 03Marathon Partners Calls for Strategic Review Process for Dr. MartensOn April 2, 2024, Marathon Partners Equity Management, LLC and its affiliated investment funds announced that they recently delivered a letter to Chairman Paul Mason and the Board of Directors, urging the Board to commence a process of evaluating alternatives to maximize shareholder value, including a potential sale of Dr. Martens plc. In the letter to the Board, Marathon Partners recommended that the Company’s Board hire an advisor and commence a strategic review process, including a potential sale or merger of the Company to interested parties, with the express goal of maximizing shareholder value. Marathon Partners stated that prior to the release of its letter, it held discussions with multiple Directors of the Company to privately resolve these matters. Marathon Partners also stated that while these conversations were friendly and productive, they did not lead to a satisfactory resolution of important shareholder issues.
お知らせ • Feb 27Giles Wilson to Join Dr. Martens plc as CFO on May 27, 2024Dr. Martens plc announced that Giles Wilson, who has been appointed to the role of Chief Financial Officer (CFO), will join the business and Board on 27th May 2024 and will present the fiscal year 2024 results on 30th May 2024.
お知らせ • Nov 30Dr. Martens plc Approves Interim Dividend, Payable on 2 February 2024Dr. Martens plc has approved and the Company has declared an interim dividend of 1.56p per share (2023: 1.56 pence). The interim dividend will be paid to shareholders on the register as at 5 January 2024 with payment on 2 February 2024.
お知らせ • Nov 17+ 1 more updateDr. Martens plc Announces Management ChangesDr. Martens plc announced that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees. The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth. Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.
お知らせ • Nov 14Dr. Martens plc to Report Fiscal Year 2024 Results on May 30, 2024Dr. Martens plc announced that they will report fiscal year 2024 results on May 30, 2024
お知らせ • Jun 01+ 2 more updatesDr. Martens plc to Report First Half, 2024 Results on Nov 30, 2023Dr. Martens plc announced that they will report first half, 2024 results on Nov 30, 2023
お知らせ • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).
お知らせ • Jul 14Dr. Martens plc to Report Fiscal Year 2023 Results on Jun 01, 2023Dr. Martens plc announced that they will report fiscal year 2023 results on Jun 01, 2023